ParagonRx Files with FDA REMS Panel Interim Analysis for Opioid Drugs Study
WILMINGTON, Del., July 15 /PRNewswire/ -- ParagonRx, a healthcare consulting leader in risk management and the appropriate use of drugs, has filed its interim analysis of a study that shows how its proprietary approach to risk management can help manufacturers of opioid drugs
meet FDA standar...
New drugs faster from natural compounds: A UC San Diego breakthrough
Researchers have invented computational tools to decode and rapidly determine whether natural compounds collected in oceans and forests are newor if these pharmaceutically promising compounds have already been described and are therefore not patentable.
This University of California, San Diego ...
Global Prescription Drugs Market to Cross $897 Billion by 2015, According to New Report by Global Industry Analysts, Inc.
GIA announces the release of a comprehensive global report on Prescription Drugs
market. The global prescription drugs
market is witnessing a significant deceleration in growth. Key factors slowing down growth in the global prescription drugs
market include economic downturn, increasing number of...
Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August
Advisory Committee to Review Denosumab Data
THOUSAND OAKS, Calif., June 22 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN ) today announced that the U.S. Food and Drug Administration (FDA) has asked the company to participate in a meeting of the Reproductive Health Drugs
HealthCore Responds to Need for Real-world Health Outcomes Information on Drugs and Devices with Physician Network and Prospective Effectiveness Research
WILMINGTON, Del., May 18 /PRNewswire/ -- HealthCore, Inc. is developing the Integrated Research Network (IRN(SM)) - a collaborative community of practicing physicians who participate in real-world prospective effectiveness research - in response to increasing need from industry and government to u...
NovaBay and Galderma Enter Into Global Agreement to Develop and Commercialize NovaBay's Novel Aganocide Drugs for Major Dermatological Conditions
- Up to $50 Million Potential Milestones plus Double Digit Royalties on Future Sales -
- Company to Host Conference Call at 11:00 a.m. ET Today -
EMERYVILLE, Calif., March 25 /PRNewswire-FirstCall/ -- NovaBay Pharmaceuticals, Inc. (NYSE Amex: NBY ), a mid-stage biopharmaceutical comp...
New label-free method tracks molecules and drugs in live cells
CAMBRIDGE, Mass. -- A new type of highly sensitive microscopy developed by researchers at Harvard University could greatly expand the limits of modern biomedical imaging, allowing scientists to track the location of minuscule metabolites and drugs
in living cells and tissues without the use of any...
Osteoporosis Drugs Increase Risk for Heart Problems
Irregular Heartbeat Is Side Effect of Common Osteoporosis Medications
PHILADELPHIA, Oct. 27 /PRNewswire/ -- People who take bisphosphonates
for osteoporosis may be at risk for serious atrial fibrillation (AF), or
irregular heartbeats, according to a new study. The research, presented at
Pharma Opinions Site Reviews the Breakthrough Drugs of Pharmaceutical Companies
Quick glance at the latest new drugs. Pharma Opinions unveils a new site were top notch biotech companies will see their new approved products reviewed and commented.
Costa de Caparica, Portugal (PRWEB) October 21, 2008 -- A new blog review on the most recent approved ...
Lumiphore Partners with Biophor Diagnostics, Inc. to Develop Tests for Drugs of Abuse; Appoints Ibis Biosciences Founder David J. Ecker to Board
RICHMOND, Calif., Oct. 1 /PRNewswire/ -- Lumiphore, Inc., a
biotechnology leader in the development of new proprietary fluorescent
metal-lanthanide technology for use in high-value applications, announced
that it has signed an exclusive agreement with Biophor Diagnostics, Inc.,
Redwood City, C...
Mergent, Inc. Announces Changes to the HealthShares(TM) European Drugs Index
NEW YORK, Aug. 11 /PRNewswire/ -- Mergent, Inc., administrator for the
HealthShares(TM) Indexes, a series of 20 underlying indexes for the
HealthShares(TM) Exchange Traded Funds, today announced the following
change effective on the opening of trading on Thursday August 14, 2008:
Biotest AG (F...
Teaching old drugs new tricks
Researchers from the European Molecular Biology Laboratory (EMBL) discovered a new way to make use of drugs' unwanted side effects. They developed a computational method that compares how similar the side effects of different drugs
are and predicts how likely the drugs
act on the same target molec...
Avastin Used in Combination with Drugs from Bristol-Myers Squibb Has Advantages in Survival Rates Over the Current Sales-Leading Therapy for Advanced Ovarian Cancer
Avastin Used in Combination with Taxol and Paraplatin Will Become the
Clinical Gold Standard Treatment by 2011, According to a New Report from Decision Resources
WALTHAM, Mass., April 23 /PRNewswire/ -- Decision Resources, one of the
world's leading research and ad...
BioDuro & The National Center for Safety Evaluation of Drugs Received Full AAALAC Accreditation
BEIJING, April 18 /PRNewswire/ -- BioDuro & The National Center for
Safety Evaluation of Drugs
(NCSED, the "Center") in Beijing announce their
receipt of full AAALAC accreditation. BioDuro and the Center collaborate to
offer preclinical toxicology and large animal DMPK for clients worldwide.
Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
- Scientific Presentation at the 99th Annual Meeting of the American Association for Cancer Research (AACR) -
TORONTO, April 16 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc.
("Lorus") (TSX: LOR; AMEX: LRP), a biopharmaceutical company specializing
in the research, developme...
YM BIOSCIENCES ANNOUNCES PRESENTATIONS FOR TWO OF ITS ANTI-CANCER DRUGS AT AACR ANNUAL MEETING
MISSISSAUGA, ON, April 11 /PRNewswire-FirstCall/ - YM BioSciences Inc.
(AMEX: YMI , TSX: YM, AIM: YMBA), an oncology company that identifies,
develops and commercializes differentiated products for patients worldwide,
today announced that posters describing research conducted on two of its
Pyratine-6(TM) Study Published in Journal of Drugs in Dermatology
NAPA, Calif., Feb. 26 /PRNewswire-FirstCall/ -- Senetek PLC (OTC
Bulletin Board: SNKTY), a Life Sciences company engaged in the development
of technologies that target the science of healthy aging, today announced
that results of a clinical study of Pyratine-6(TM) have been featured in
So Long, Old Friend: The End of the Blockbuster Drug Era? What 2008 Holds for Bringing Drugs to Market
Hoffmann-La Roche Inc. CEO George Abercrombie, Pfizer R&D Head Martin
Mackay, HHS Deputy Secretary Tevi Troy, Former CMS Administrator & FDA
Commissioner Mark McClellan Headline Agenda at FDA/CMS Summit 2007
WASHINGTON, Nov. 15 /PRNewswire-USNewswire/ -- It's shaping up to be a
record year f...
Isis Pharmaceuticals and Thomas, McNerney & Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory Conditions
- Isis will own 18 percent of Altair and will receive milestones and royalties on antisense drugs
developed by Altair - Altair to conduct clinical development of ISIS 369645 for asthma
CARLSBAD, Calif. and SAN FRANCISCO, Oct. 16 /PRNewswire-FirstCall/ --
Isis Pharmaceuticals, In...
Thomson Scientific Publishes 'Who Is Making The Biggest Splash?' - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
Novartis Takes Top Spot, Previously Held by GlaxoSmithKline Since June 2006
PHILADELPHIA and LONDON, Oct. 16 /PRNewswire-FirstCall/ -- Thomson
Scientific, part of The Thomson Corporation (NYSE: TOC ; TSX: TOC) and
leading provider of information solutions to the worldwide research and
Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
- Includes license of two antisense drugs
in development targeting glucagon receptor and glucocorticoid receptor
- Includes research collaboration to identify antisense drugs
to inhibit additional targets to treat metabolic diseases - Conference call webcast Thursd...
NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS
- Results from a randomized Phase IIb trial reported at 2009 ASCO Annual
MISSISSAUGA, ON, June 1 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI , TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio ...
China Sky One Medical, Inc. Obtains Production Approval for Two New Drugs
HARBIN, China, May 26 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical,
Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI ), a leading
fully integrated pharmaceutical company in the People's Republic of China
("PRC"), today announced that it recently obtained production appro...
ImQuest BioSciences and Arisyn Therapeutics Announce Strategic Partnership to Develop Infectious Disease and Cancer Drugs
FREDERICK, Md., April 29 /PRNewswire/ -- ImQuest BioSciences and Arisyn Therapeutics jointly announced today that they have entered into a strategic drug development partnership to provide support necessary to develop Arisyn's portfolio of novel inhibitors for the treatment of infectious disease a...
New Insights into the Mechanism of Action of Antipsychotic Drugs
ROCKVILLE, Md., March 10 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA ) reports the publication in Schizophrenia Research , the official journal of the Schizophrenia International Research Society, of a manuscript entitled "Common effect of antipsychotics on the biosynthes...
Safer nanoparticles spotlight tumors, deliver drugs
Small is promising when it comes to illuminating tiny tumors or precisely delivering drugs, but many worry about the safety of nano-scale materials. Now a team of scientists has created miniscule flakes of silicon that glow brightly, last long enough to slowly release cancer drugs, then break down...
VAP Cholesterol Test Helps In Search For New Heart Disease Drugs
Peer-reviewed journal, Science, reports that advanced cholesterol test aids in identifying connection between improved lipid profile and heart protection
BIRMINGHAM, Ala., Feb. 16 /PRNewswire/ -- Using the VAP Cholesterol Test from Atherotech, Inc., University of Maryland researchers h...
China Sky One Medical, Inc. Obtains Production Rights for Nine New Drugs
HARBIN, China, Nov. 13 /Xinhua-PRNewswire-FirstCall/ -- China Sky One
Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI ), a
leading fully integrated pharmaceutical company producing over-the-counter
drugs in the People's Republic of China ("PRC"), announced today that it...
ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
EXTON, Pa., July 8 /PRNewswire-FirstCall/ -- ViroPharma Incorporated
(Nasdaq: VPHM ) has been informed by U.S. Food and Drug Administration (FDA)
that the July 23, 2008 meeting of its Advisory Committee for Pharmaceutical
Science and Clinical Pharmacology is not intended to discuss specifical...
Lixte Biotechnology Holdings Announces Extension of Its Cooperative Research and Development Agreement With The National Institute of Neurological Disorders and Stroke, National Institutes of Health, for Development of Anti-Brain Cancer Drugs
EAST SETAUKET, N.Y., June 25 /PRNewswire-FirstCall/ -- Lixte
Biotechnology Holdings (OTC Bulletin Board: LIXT) announced today that the
National Institute of Neurological Disorders and Stroke (NINDS), National
Institutes of Health (NIH) and Lixte Biotechnology Holdings, Inc. extended
AngioGenex Appoints New CEO to Direct Development of Anti-Cancer Drugs
NEW YORK, June 10 /PRNewswire-FirstCall/ -- AngioGenex Inc. (OTC
Bulletin Board: AGGX.OB) a New York-based biotechnology company, and the
leader in the field of Id targeted anti-angiogenic drugs, announced the
appointment of William Garland PhD as Chief Executive Officer. Dr. Garland,
Champions Biotechnology and ImClone Systems Establish Agreement for Preclinical Evaluation of Oncology Drugs
ARLINGTON, Va., May 7 /PRNewswire-FirstCall/ -- Champions
Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the
development of advanced preclinical platforms and tumor specific data to
enhance the value of oncology drugs, today announced that it has
established an agreement ...
Research Using Thermo Fisher Scientific RNA-Interference Technology Unveils Potential New Targets for HIV Drugs
Harvard Medical School Researchers Used Thermo Scientific Dharmacon siRNA
to Identify 273 Human Proteins Needed for Reproduction of the Virus that Causes AIDS
WALTHAM, Mass., Jan. 31 /PRNewswire-FirstCall/ -- Thermo Fisher
Scientific Inc., the world leader in serv...
Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
- HGS acquires exclusive rights to develop and commercialize small-molecule IAP inhibitors in oncology -
- Lead compound AEG40826 works synergistically with HGS TRAIL receptor antibodies to enhance anticancer activity of both drugs
- IAP inhibitors also show prom...
First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs
SAN FRANCISCO, Oct. 24 /PRNewswire-FirstCall/ -- Cell Therapeutics,
Inc. (CTI) (Nasdaq and MTAX: CTIC) announced preclinical data presented at
the 19th annual AACR-NCI-EORTC Symposium show its bis-platinate drug
candidates, CT-47613 and CT-47609, kill tumors refractory to currently
Tapeworm's Chemical Trick Could Make Drugs More Effective
MADISON, WI - To survive and thrive in a decidedly hostile environment, the lowly tapeworm uses a chemical trick to evade the propulsive nature of its intestinal home.
Capitalizing on that tapeworm chemistry, scientists at the University of Wisconsin-Madison believe they may have found a way to ...
Why are new drugs failing?
The FDA's recent decision to pull Pfizer Cox-2 inhibitor Bextra from the marketplace clearly jolted both Pfizer and the market. Pfizer was initially caught up in the Merck Vioxx dilemma months ago and its stock has declined from $38 per share a year ago to under $25 per share in February. It has ...
Femtogram Sensitivity of the Antipsychotic Drugs Raclopride and Ritanserin Using a Varian 1200L LC/MS/MS
J. Beck and C. Schmidt
Ritanserin (Tisterton) is a serotonin-2 antagonist drug shown to be effective in the treatment of anxiety and depression 1 while Raclopride acts as a dopamine D2 receptor antagonist. 2 These two compound...
Rapid Screening of Amphetamine Drugs in Urine by Positive Ion Electrospray LC/MS/MS
Z. Yang and S. Sadjadi, Varian, Inc.
are often abused and misused in sports, in the work place, and by recreational users. Forensic, clinical, and doping laboratories are frequently asked to analyze for the presence of amphetamines in ...
A simple and rapid LC-MS/MS method for the simultaneous determination of nine antiretroviral drugs commonly used in Europe (protease Inhibitors and non-nucleoside reverse transcriptase inhibitors)
In clinical research, the monitoring of protease inhibitor (PI) and non-nucleoside reverse transcriptase inhibitor (NNRTI) antiretroviral drugs
is of significant interest due to the importance of assessing inter-individual and intra-individual metabolism variability. ...